Duality Advisers LP Purchases Shares of 3,182 DaVita Inc. (NYSE:DVA)

Duality Advisers LP bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,182 shares of the company’s stock, valued at approximately $333,000.

A number of other large investors have also recently modified their holdings of DVA. Deutsche Bank AG boosted its stake in shares of DaVita by 421.8% during the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares in the last quarter. Invesco Ltd. boosted its stake in shares of DaVita by 21.3% during the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of DaVita by 148.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 365,701 shares of the company’s stock valued at $34,570,000 after purchasing an additional 218,693 shares in the last quarter. Northern Trust Corp boosted its stake in shares of DaVita by 15.7% during the 3rd quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after purchasing an additional 113,508 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of DaVita by 2,178.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock valued at $11,379,000 after purchasing an additional 103,856 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Up 0.5 %

Shares of DaVita stock opened at $133.50 on Friday. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19. The stock has a market capitalization of $11.71 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 1.18 and a beta of 1.04. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $141.54. The company has a 50-day simple moving average of $132.12 and a two-hundred day simple moving average of $110.47.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same period in the previous year, the company earned $1.11 earnings per share. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. On average, analysts anticipate that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DVA. TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. StockNews.com raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Barclays began coverage on shares of DaVita in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective on the stock. Truist Financial boosted their price objective on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Finally, UBS Group boosted their price objective on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DaVita currently has an average rating of “Moderate Buy” and an average price target of $118.50.

Insider Activity

In other news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the transaction, the insider now directly owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock valued at $16,551,071 over the last three months. Insiders own 1.40% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.